BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 18769733)

  • 1. Trogocytosis of MHC-I/peptide complexes derived from tumors and infected cells enhances dendritic cell cross-priming and promotes adaptive T cell responses.
    Zhang QJ; Li XL; Wang D; Huang XC; Mathis JM; Duan WM; Knight D; Shi R; Glass J; Zhang DQ; Eisenbach L; Jefferies WA
    PLoS One; 2008 Aug; 3(8):e3097. PubMed ID: 18769733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spotlight on TAP and its vital role in antigen presentation and cross-presentation.
    Mantel I; Sadiq BA; Blander JM
    Mol Immunol; 2022 Feb; 142():105-119. PubMed ID: 34973498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacterial antigen delivery systems: phagocytic processing of bacterial antigens for MHC-I and MHC-II presentation to T cells.
    Svensson M; Pfeifer J; Stockinger B; Wick MJ
    Behring Inst Mitt; 1997 Feb; (98):197-211. PubMed ID: 9382741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining the antigen processing components TAP and Tapasin elicits enhanced tumor-free survival.
    Lou Y; Basha G; Seipp RP; Cai B; Chen SS; Moise AR; Jeffries AP; Gopaul RS; Vitalis TZ; Jefferies WA
    Clin Cancer Res; 2008 Mar; 14(5):1494-501. PubMed ID: 18316574
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Del Balzo D; Capmany A; Cebrian I; Damiani MT
    Front Immunol; 2021; 12():662096. PubMed ID: 33936099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IFN-γ treatment protocol for MHC-I
    Stifter K; Krieger J; Ruths L; Gout J; Mulaw M; Lechel A; Kleger A; Seufferlein T; Wagner M; Schirmbeck R
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading.
    Robson NC; Beacock-Sharp H; Donachie AM; Mowat AM
    Immunology; 2003 Jul; 109(3):374-83. PubMed ID: 12807483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TAP dysfunction in dendritic cells enables noncanonical cross-presentation for T cell priming.
    Barbet G; Nair-Gupta P; Schotsaert M; Yeung ST; Moretti J; Seyffer F; Metreveli G; Gardner T; Choi A; Tortorella D; Tampé R; Khanna KM; García-Sastre A; Blander JM
    Nat Immunol; 2021 Apr; 22(4):497-509. PubMed ID: 33790474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells.
    Groh V; Li YQ; Cioca D; Hunder NN; Wang W; Riddell SR; Yee C; Spies T
    Proc Natl Acad Sci U S A; 2005 May; 102(18):6461-6. PubMed ID: 15824323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
    Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
    Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Priming of immune responses against transporter associated with antigen processing (TAP)-deficient tumours: tumour direct priming.
    Li XL; Zhang D; Knight D; Odaka Y; Glass J; Mathis JM; Zhang QJ
    Immunology; 2009 Nov; 128(3):420-8. PubMed ID: 20067541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiency of peptide presentation by dendritic cells compared with other cell types: implications for cross-priming.
    Zehn D; Cohen CJ; Reiter Y; Walden P
    Int Immunol; 2006 Dec; 18(12):1647-54. PubMed ID: 17035346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shaping of T Cell Functions by Trogocytosis.
    Nakayama M; Hori A; Toyoura S; Yamaguchi SI
    Cells; 2021 May; 10(5):. PubMed ID: 34068819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type I interferon activates MHC class I-dressed CD11b
    Duong E; Fessenden TB; Lutz E; Dinter T; Yim L; Blatt S; Bhutkar A; Wittrup KD; Spranger S
    Immunity; 2022 Feb; 55(2):308-323.e9. PubMed ID: 34800368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation.
    Blachère NE; Darnell RB; Albert ML
    PLoS Biol; 2005 Jun; 3(6):e185. PubMed ID: 15839733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain.
    Lizée G; Basha G; Tiong J; Julien JP; Tian M; Biron KE; Jefferies WA
    Nat Immunol; 2003 Nov; 4(11):1065-73. PubMed ID: 14566337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel pathway of antigen presentation by dendritic and endothelial cells: Implications for allorecognition and infectious diseases.
    Smyth LA; Herrera OB; Golshayan D; Lombardi G; Lechler RI
    Transplantation; 2006 Jul; 82(1 Suppl):S15-8. PubMed ID: 16829787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocytic Recycling of MHC Class I Molecules in Non-professional Antigen Presenting and Dendritic Cells.
    Montealegre S; van Endert PM
    Front Immunol; 2018; 9():3098. PubMed ID: 30666258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus-like particles access major histocompatibility class I and II antigen presentation pathways in primary dendritic cells.
    Moffat JM; Cheong WS; Villadangos JA; Mintern JD; Netter HJ
    Vaccine; 2013 Apr; 31(18):2310-6. PubMed ID: 23473776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo.
    den Haan JM; Lehar SM; Bevan MJ
    J Exp Med; 2000 Dec; 192(12):1685-96. PubMed ID: 11120766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.